ヨーロッパにおける先天性心不全:罹患率と産前死亡率,2000年から2005年
Helen Dolk1, Maria Loane, Ester Garne
1Professor of Epidemiology and Health Services Research, University of Ulster, Co Antrim, Northern Ireland, UK. h.dolk@ulster.ac.uk
Circulation
|February 16, 2011
まとめ
生まれながらの心不全 (CHD) は,ヨーロッパでは1000人の出生のうち8.0人に影響し,有意な変動があります. 早期診断と予防は,毎年推定3万9000人の慢性疾患に関連する死亡と解雇を減らすために極めて重要です.
科学分野:
- 心臓病学 心臓病学
- 公衆衛生は公衆衛生である.
- 遺伝学 遺伝学とは
背景:
- 生まれながらの心不全 (CHD) は,世界的な健康上の重大な懸念を代表しています.
- CHDの罹患率と結果を理解することは,公衆衛生イニシアチブにとって不可欠です.
研究 の 目的:
- ヨーロッパにおける先天性心不全 (CHD) の罹患率を決定する.
- CHDに関連した胎児および胎内死亡率を評価する.
- 欧州各国におけるCHDの罹患率とアウトカムの変動を分析する.
主な方法:
- 欧州16カ国の29の集団ベースの先天性異常登録所からデータを収集した.
- この研究では,2000年から2005年の間に生まれた330万人の出生データを分析した.
- CHD症例には,生産,胎児死亡 (妊娠20週以上),胎児異常 (TOPFA) による妊娠中絶が含まれる.
主要な成果:
- CHDの平均総罹患率は1000出産当たり8.0であり,生児の罹患率は1000出産当たり7.2であった.
- 重度の非染色体性CHDは1000出産の2.0人に発生し,40%が産前診断され,14%がTOPFAに結果しました.
- ダウン症候群に関連したCHDは,生児1000人に0.5人に発生し,国によって4倍以上の変動を示しています.
結論:
- EUでは毎年,約3万6千人の子供が,心臓病で生まれ,さらに3千人の子供が (胎児,終末期,新生児) 死亡しています.
- 初期予防と病原遺伝学研究への投資は,心血管疾患の負担を軽減するために不可欠です.
- 産前診断から成人期までの心臓医療サービスの改善は,より良い結果を得るために不可欠です.
関連する概念動画
01:27Mitral Valve Prolapse I: Introduction
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
01:08Prevalence and Incidence
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...